A Major 2025 Study Shows Stronger Cholesterol Control Can Prevent Heart Attacks—Even Before They Happen

The Food and Drug Administration has expanded approval for evolocumab (Repatha), a powerful cholesterol-lowering drug, to prevent heart attacks and strokes in high-risk adults who don't yet have heart disease. This marks the first time a PCSK9 inhibitor has been approved for primary prevention, potentially helping millions of Americans avoid their first cardiovascular event.

What Makes This Cholesterol Drug Different?

Evolocumab belongs to a class of medications called PCSK9 inhibitors, which work differently than traditional cholesterol drugs like statins. While statins block cholesterol production in the liver, PCSK9 inhibitors help the liver remove more low-density lipoprotein (LDL) cholesterol—the "bad" cholesterol—from the bloodstream.

The drug was originally approved in 2015 solely for lowering LDL cholesterol levels. It gained its first cardiovascular prevention approval based on the FOURIER trial, which showed that adding evolocumab to usual care reduced the risk of major adverse cardiovascular events (MACE) by 15% in patients who already had stable heart disease.

Who Can Benefit From This Expanded Approval?

The new indication covers high-risk adults without established cardiovascular disease who have elevated LDL cholesterol levels. The drug is now approved to reduce the risk of several serious events:

• Cardiovascular death: Fatal heart attacks or other heart-related deaths
• Heart attacks: Both fatal and non-fatal myocardial infarctions
• Strokes: Brain attacks caused by blocked blood vessels
• Unstable angina: Severe chest pain requiring hospitalization
• Coronary revascularization: Procedures to restore blood flow to the heart

This expansion is significant because it shifts the focus from treating existing heart disease to preventing it entirely. Currently, evolocumab is the only PCSK9 inhibitor approved for reducing cardiovascular events in patients without established disease, giving it a competitive edge over alirocumab (Praluent), which remains limited to patients with existing heart disease.

What Does the Research Show About Prevention?

While this approval represents a major step forward, researchers are still gathering data on evolocumab's effectiveness in primary prevention. The ongoing VESALIUS-CV study is randomizing approximately 12,000 patients with high cardiovascular risk but no prior heart attacks or strokes to receive either evolocumab plus usual care or usual care alone.

The broader research landscape in 2025 has reinforced the critical importance of managing cardiovascular risk factors before disease develops. A landmark study published in The New England Journal of Medicine analyzed over 2 million people worldwide and found dramatic differences in lifespan based on risk factor control.

The study revealed that five modifiable risk factors account for about half the global burden of cardiovascular disease: abnormal body mass index (BMI), high systolic blood pressure, excess non-HDL cholesterol levels, smoking, and diabetes. People who controlled all these factors at age 50 lived significantly longer than those who didn't.

Women with none of these risk factors lived 14.5 years longer than women with all the risk factors, while men without the risk factors lived nearly 12 years longer. The research also showed that quitting smoking in one's mid-50s to age 60 had the most impact on delaying death, while controlling hypertension was the most powerful way to live longer without cardiovascular disease.

This expanded approval for evolocumab represents a significant advancement in preventive cardiology, offering a new tool for high-risk patients to avoid their first cardiovascular event. As the medical community continues to emphasize prevention over treatment, medications like evolocumab may play an increasingly important role in keeping hearts healthy before problems begin.